Combination treatment increases survival in high-risk PCa patients
A combination of brachytherapy and external radiation plus androgen deprivation gives prostate cancer patients with high-risk disease a better chance of survival than patients treated with radiation alone, according to a study in the International Journal of Radiation Oncology*Biology*Physics (2005; 61:32-43).
Jonathan E. Rosenberg, MD, discusses the FDA approval of perioperative durvalumab plus enfortumab vedotin and considerations for treatment selection in cisplatin-ineligible MIBC.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.